Chinese
Japan
English
Dose-response relationship
One week pharmacokinetics method development
Pharmacokinetic studies focus on the fate of drugs in vivo, and service as the key parameter for PK-PD and PK-Tox studies. Through the detection of drug exposure level in vivo, ProBio establish PK-PD correlation, to support antibody/protein engineering, optimize dose and frequency during in vivo efficacy studies. ProBio can also provides RO assays to guide more suitable clinical dose design and performs different administrate route for biological drugs, conducts PK, ADA testing, tissue distribution assays for comprehensive PK research.
Non-human primate (NHP)–based pharmacokinetic (PK) studies are critical for predicting human PK, supporting toxicology dose selection, and reducing late-stage development risk. However, in early discovery, NHP PK studies are traditionally limited by cost, supply, and timelines.
ProBio’s NHP Non-GLP PK Study Service addresses these challenges by enabling high-quality, cost-effective NHP PK studies that are practical and accessible at the discovery stage
Traditional in vitro BBB models often fail to predict in vivo brain exposure. At ProBio, our In Vivo Pharmacokinetics Platform for CNS Drugs enables accurate assessment of brain penetration and brain-region distribution, providing translational data to support candidate selection, de-risk development, and accelerate clinical progress.
A. Antibody biosimilar were administered into monkey by I.V., the antibody concentration was determined by PD1 based on ELISA, and the PK parameters were calculated by WinNonlin.
A. According to the results, 5ug/mL and 1ug/mL test antibody can full saturate the target in monkey and human WBC, respectively.